- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
EMA: Already 325 rare cases of thrombosis after vaccination worldwide
EMA: Already 325 rare cases of thrombosis after vaccination worldwide. According to UDN, the European Medicines Agency (EMA) pointed out that there have been more than 300 rare cases of low platelet thrombosis after vaccination with the COVID-19 vaccine.
On April 21, local time, EMA’s data analysis department chief Alett released data showing that 287 cases involved AstraZeneca vaccine, 8 cases involved Johnson & Johnson vaccine, 25 cases involved Pfizer/BioNtech vaccine, and 5 cases involved Moderna vaccine.
The statement issued by EMA stated that the Pharmacovigilance Risk Assessment Committee concluded after investigation and found that there may be a link between the vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and the occurrence of thrombosis, but insisted that its benefits still outweigh the risks.
The committee believes that the product information of Johnson & Johnson vaccine should list the occurrence of blood clots and low platelet counts as “very rare” side effects. EMA announced on the 7th of this month that thrombosis and low platelet count should be listed as a rare side effect of the AstraZeneca vaccine.
The statement pointed out that the committee has evaluated all existing evidence, including 8 serious cases of thrombosis and low platelets after vaccination from Johnson & Johnson in the United States. In addition, the cases reviewed in this review are “very similar” to those in which blood clots occurred after the AstraZeneca vaccine.
EMA found that all Johnson & Johnson vaccine vaccinators with blood clots were adults under the age of 60, mostly women. Symptoms appeared within three weeks after receiving the Johnson & Johnson vaccine. In most cases, the blood clots were in the brain and abdomen. The situation is similar to that of the AstraZeneca vaccine. Only one dose of Johnson & Johnson vaccine is required.
EMA Chairman Strauss said at a press conference on the 20th: “After careful review of the cases and other existing evidence, we confirmed that the occurrence of these blood clots is a very rare side effect of the vaccine. It is still impossible to confirm the cause of such side effects. Specific risk factors, but the vaccine is effective in preventing infection with the new coronavirus.”
She also pointed out that although the risk of such side effects is very low, health care workers and vaccinators must be aware of the risk and pay close attention to possible symptoms after vaccination.
(source:internet, reference only)